Treatment of Abdominal Desmoplastic Small Round Cell Tumor Induces Acute Myeloid Leukemia-M5: A Case Report and Literature Review
Lan Liu,Meizuo Zhong,Xuan Zhou,Fanhua Kang,Yong Long,Junfeng Li
DOI: https://doi.org/10.2147/ott.s434286
IF: 4
2024-02-28
OncoTargets and Therapy
Abstract:Lan Liu, 1 Meizuo Zhong, 1, 2 Xuan Zhou, 3 Fanhua Kang, 4 Yong Long, 1 Junfeng Li 1 1 Department of Oncology, Xiangya Changde Hospital, Changde, Hunan, People's Republic of China; 2 Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China; 3 Department of Hematology, Xiangya Changde hospital, Changde, Hunan, People's Republic of China; 4 Department of Pathology, Xiangya Changde Hospital, Changde, Hunan, People's Republic of China Correspondence: Junfeng Li, Email Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive malignancy. Most patients are diagnosed at a late stage with poor prognosis. The treatment usually includes combined intensive chemotherapy, cytoreductive surgery, radiotherapy, and targeted therapy. Due to the low incidence rate and dismal survival, there is currently a lack of case reports on DSRCT with concurrent leukemia. We report a case of a young patient who achieved disease stabilization for 14 months after receiving 6 cycles of chemotherapy and whole abdominal radiation therapy (WART), followed by consolidation treatment with anlotinib. However, the treatment was terminated due to the development of Acute Myeloid Leukemia-M5 (AML-M5). Multimodal therapy may provide a survival benefit for rare tumors that lack standard treatment. However, intensive chemotherapy and extensive radiotherapy carry a risk of inducing secondary malignancies. This is the first reported case of concurrent DSRCT and AML-M5 with short intervals between onset. Keywords: desmoplastic small round cell tumor, whole abdominal radiation therapy, anlotinib, therapy-related acute myeloid leukemia Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive sarcoma with an annual incidence of approximately 0.2–0.5 per 100,000 1. It often occurs in male children and adolescents, with a peak incidence between 20 and 25 years of age, and frequently involves the abdomen and pelvic cavity with distant metastasis. Without hallmark clinical manifestations, most patients are diagnosed at an advanced stage and are difficult to treat with curative resection. Treatment strategies include maximum cytoreductive surgery, high-intensity systemic chemotherapy, targeted therapy, intraperitoneal hyperthermic chemotherapy, and radiation therapy; however, the treatment effect is unsatisfactory and the overall prognosis is poor. Therapy-related acute myeloid leukemia (t-AML) is a late complication of cytotoxic chemotherapy and/or radiotherapy for malignant and non-malignant diseases. 2 t-AML accounts for about 7% of AML patients 3–5 and is mostly associated with non-Hodgkin's lymphoma. It is estimated that the incidence of t-AML will increase with more patients receiving radiotherapy and chemotherapy, and with the extension of the overall survival time for malignant tumors. In this report, we present the first case of abdominal DSRCT with widespread metastasis that was treated with comprehensive antitumor therapy and developed treatment-related acute myeloid leukemia 7 months later. The patient was a 32-year-old male who visited the hospital on March 18 th 2020, with a lower abdominal mass that had been present for more than three months. He had no medical or family history of tumors. Enhanced CT showed multiple nodules and masses in the abdominal cavity and hepatic capsule, multiple enlarged lymph nodes in the bilateral diaphragmatic angle, retroperitoneum, bilateral iliac vessels, and multiple bone metastases (Figure 1). Dense radioactive shadows were detected on the bone scan, indicating a high possibility of bone metastasis. No obvious abnormalities were found during the colonoscopy. CT-guided puncture biopsy of the lower abdominal mass was performed, and the pathology results indicated DSRCT (Figure 2). Immunohistochemistry revealed positive expression of EMA, Vimentin, Desmin, NSE, CD99 and CK (pan), and next-generation sequencing (NGS) of the tissue samples showed a TERT gene promoter region mutation (C.-263g > A) and EWSR1 rearrangement (WT1-EWSR1) (Figure 2). No genetic abnormalities were seen on the NGS of the blood samples (Burning Rock Dx, OncoScreen Plus Panel). Figure 1 ( A ) Abdominal and pelvic CT scan reveals multiple nodules and masses present on the liver capsule (red arrow), ( B ) the largest lesion measuring approximately 87mm x 53mm and located in the mid-abdomen (red arrow), ( C – F ) there are also multiple nodules and mass lesions within the abdominal cavity (red arrow). Figure 2 The pictures of tumor pathology sections: ( A ) HE×10, ( B ) HE×20, -Abstract Truncated-
oncology,biotechnology & applied microbiology